Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Tsukuba
Clinical trial register · Japan

Clinical Trials in Tsukuba, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Japan and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2493 matching records held by the registry are in this view. Synced 22 Oct 2026, 03:19 UTC
2493
Studies in scope
all four open statuses
1263
Recruiting now
open to new participants
349
Lead sponsors
across recruiting studies
Top sites
Fukuoka 551 Nagoya 517 Sapporo 398 Tokyo 369 Osaka 348
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Merck Sharp & Dohme LLC8 AbbVie4 Novartis Pharmaceuticals3 Seagen, a wholly owned subsidiary of Pfizer3 Bristol-Myers Squibb3
Site location
Fukuoka551 Nagoya517 Sapporo398 Tokyo369 Osaka348
All 926 locations
Target enrolment
to

Trials with a site in Tsukuba

46 of 2493 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Japan
Start
Recruiting
Pemafibrate for Symptomatic ICAS RCT
NCT07562178Intracranial Atherosclerotic Disease (ICAD), Hypertriglyceridaemia, Stroke (CVA) or TIA
DrugPemafibrate
Tokyo Women's Medical University
Not applicable
270
Toyoake, Yachiyo, Fukuyama, Hiroshima, Kobe, Tsukuba, Hizume, Kagoshima
2026-05-26
Recruiting
Merck Sharp & Dohme LLC
Phase 3
590
Nagoya, Hirosaki, Tōon, Sapporo, Kobe, Tsukuba, Kita-gun, Kawasaki
2026-04-23
Recruiting
Astellas Pharma Global Development, Inc.
Phase 2
240
Gifu, Kobe, Tsukuba, Kawasaki, Bunkyo-ku, Koto-ku, Ube, Kyoto
2026-03-12
Recruiting
Alnylam Pharmaceuticals
Observational
2,000
Bunkyō City, Kumamoto, Kurume, Matsumoto, Sendai, Shinjuku, Suita, Tsukuba
2026-01-09
Recruiting
Sanofi
Phase 2
144
Nagoya, Tsukuba, Koshigaya, Tokyo
2025-12-29
Recruiting
argenx
Observational
70
Tsukuba, Kawasaki-Shi, Sendai, Hanamaki, Narita
2025-12-19
Recruiting
argenx
Phase 2
70
Tsukuba, Kawasaki-shi, Sendai, Hanamaki, Narita
2025-12-19
Active, closed
Fabhalta Capsules Specified Drug-use Survey
NCT07156149C3 Glomerulopathy
Novartis Pharmaceuticals
Observational
33
Nagoya, Toyoake, Hirosaki, Chiba, Fukuoka, Kitakyushu, Sapporo, Tsukuba
2025-09-17
Active, closed
Bayer
Phase 3
36
Kurume, Himeji, Kobe, Tsukuba, Morioka, Sagamihara, Yokohama, Nankoku
2025-06-30
Recruiting
Amgen
Phase 3
844
Nagoya-shi, Nagoya, Sapporo, Kita Kyushu-shi, Tsukuba, Kahoku, Kanazawa, Yokohama
2025-02-25
Recruiting
Dianthus Therapeutics
Phase 3
256
Niigata, Kawasaki, Tsukuba, Kurashiki, Hirakata, Kawagoe, Ube
2025-02-10
Active, closed
AbbVie
Phase 2
150
Hirosaki, Fukushima, Tsukuba, Kanazawa
2025-01-20
Active, closed
argenx
Phase 3
631
Nagoya, Fukushima, Hiroshima, Sapporo, Nishinomiya-shi, Tsukuba, Kahoku-gun, Kanazawa
2025-01-15
Recruiting
Novartis Pharmaceuticals
Observational
30
Ōbu, Toyoake, Kurume, Sapporo, Tsukuba, Kawasaki, Yokohama, Tsu
2024-12-19
Active, closed
Merck Sharp & Dohme LLC
Phase 3
686
Nagoya, Kashiwa, Matsuyama, Tōon, Kurume, Ohta, Sapporo, Tsukuba
2024-07-24
Active, closed
Amgen
Phase 3
434
Nagoya, Sapporo, Kita Kyushu-shi, Nishinomiya-Shi, Tsukuba, Kahoku, Kanazawa, Yokohama
2024-04-08
Active, closed
Merck Sharp & Dohme LLC
Phase 3
710
Nagoya, Matsuyama, Tōon, Kurume, Otashi, Sapporo, Tsukuba, Shiwa-gun
2023-12-06
Active, closed
AbbVie
Observational
250
Matsuyama, Asahikawa, Hakodate-shi, Ryūgasaki, Tsukuba, Kagoshima, Kyoto, Sendai
2023-11-30
Recruiting
Kyoto University Hospital
Phase 2
30
Kobe, Tsukuba, Kyoto, Osaka
2023-10-01
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
412
Fukuoka, Ota-Shi, Kobe, Tsukuba, Kita-gun, Yokohama, Tokushima, Wakayama
2023-09-22
Active, closed
Bristol-Myers Squibb
Phase 3
774
Nagoya, Toyoake-shi, Kitakyushu-shi, Sapporo, Nishinomiya-shi, Tsukuba, Kahoku-gun, Kanazawa
2023-09-11
Active, closed
AbbVie
Phase 3
1,328
Fukuoka, Nishinomiya-shi, Tsukuba, Kyoto, Sendai, Ginowan-shi, Sakai-shi, Ōtsu
2023-06-21
Recruiting
Regeneron Pharmaceuticals
Phase 3
202
Nagoya, Tsukuba
2023-03-07
Active, closed
Insmed Incorporated
Phase 2/3
91
Sapporo, Kurume-shi, Tsukuba, Okayama, Suita-Shi
2023-03-07
Active, closed
A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer
NCT05567185Urinary Bladder Neoplasms, Receptors, Fibroblast Growth Factor
DrugErdafitinib
Janssen Pharmaceutical K.K.
Phase 1
5
Kanagawa, Osaka, Toyama, Tsukuba
2023-03-03
Active, closed
Genmab
Phase 3
900
Nagoya, Kashiwa-shi, Matsuyama, Fukuoka, Fukushima, Sapporo, Kobe, Tsukuba
2023-02-08
Active, closed
Alexion Pharmaceuticals, Inc.
Phase 3
80
Bunkyō City, Kyoto, Osaka, Shibuya-ku, Tsukuba
2022-10-28
Active, closed
Regeneron Pharmaceuticals
Phase 3
202
Nagoya, Ōgaki, Tsukuba, Moriguchi, Shinagawa-ku
2022-08-01
By invitation
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 2/3
600
Nagoya, Toyoake-shi, Chiba, Urayasu-shi, Kobe, Tsukuba, Kawasaki-shi, Kashihara
2022-04-05
Active, closed
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
530
Nagoya, Toyoake, Urayasu, Kurume, Amagasaki, Kobe, Tsukuba, Kanazawa
2022-03-15
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
654
Kamogawa, Kashiwa-Shi, Matsuyama, Fukuoka, Fukushima, Sapporo, Tsukuba, Kanazawa
2022-03-07
Active, closed
Merck Sharp & Dohme LLC
Phase 3
280
Kashiwa, Matsuyama, Tōon, Kurume, Otashi, Sapporo, Tsukuba, Shiwa-gun Yahaba-cho
2022-02-03
Recruiting
ARCAGY/ GINECO GROUP
Phase 2
390
Tokyo, Kashiwanoha, Kurume, Tsukuba, Niigata, Kita-ku, Shimotsuke, Ehime
2022-02-01
Active, closed
Merck Sharp & Dohme LLC
Phase 3
808
Nagoya, Hirosaki, Tsukuba, Kanazawa, Sagamihara, Yokohama, Sendai, Hamamatsu
2021-04-21
Active, closed
Pfizer
Phase 2
66
Nagoya, Kashiwa, Matsuyama, Sapporo, Akashi, Nishinomiya, Tsukuba, Yokohama
2021-04-08
Active, closed
Amplatzer Amulet LAAO vs. NOAC
NCT04226547Atrial Fibrillation, Stroke, Bleeding
DrugNOAC
Abbott Medical Devices
Not applicable
2,650
Toyohashi, Chiba, Kitakyushu, Tsukuba, Kamakura, Sendai, Kurashiki-shi, Meguro-ku
2020-07-07
Active, closed
Merck Sharp & Dohme LLC
Phase 3
520
Hirosaki, Tsukuba, Takatsuki, Nagasaki, Tokyo
2020-05-19
Active, closed
AbbVie
Phase 3
56
Chiba, Toon-shi, Maebashi, Sapporo, Tsukuba, Kita-gun, Kawasaki-shi, Yokohama
2020-02-04
Recruiting
Study of Out of Specification for Tisagenlecleucel
NCT04094311B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma
DrugTisagenlecleucel
Novartis Pharmaceuticals
Phase 3
200
Nagoya, Tōon, Gifu, Sapporo, Kobe, Nishinomiya, Tsukuba, Kita-gun
2019-11-21
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
466
Nagoya, Kashiwa, Hiroshima, Matsuyama, Fukuoka, Sapporo, Nishinomiya, Tsukuba
2019-10-02
Recruiting
Bristol-Myers Squibb
Phase 2
1,500
Hirosaki-shi, Chiba, Kashiwa-Shi, Matsuyama, Fukuoka, Kobe, Tsukuba, Kanazawa
2019-08-09
Active, closed
Merck Sharp & Dohme LLC
Phase 3
595
Kashiwa, Tsukuba, Kawasaki, Sagamihara, Yokosuka, Sendai, Tomitake, Kashihara
2019-07-24
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,397
Hirosaki, Tōon, Tsukuba, Kawasaki, Sagamihara, Yokosuka, Kashihara, Hamamatsu
2018-12-24
Active, closed
pharmaand GmbH
Phase 3
1,097
Tsukuba, Kashiwa, Kurume, Yokohama, Maebashi, Ota-shi, Naka, Akashi
2018-05-14
Recruiting
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
NCT03067181Childhood Extracranial Germ Cell Tumor, Extragonadal Embryonal Carcinoma, Germ Cell Tumor, Malignant Germ Cell Tumor
DrugsBleomycin·Cis-platinum·CDDP·Paraplatin
Children's Oncology Group
Phase 3
1,780
Sendai, Chiba-sgi, Niigata, Higashiku, Sapporo, Kobe, Tsukuba, Yokohama
2017-05-25
Active, closed
Bristol-Myers Squibb
Phase 3
1,314
Hirosaki, Chiba, Matsuyama, Fukuoka, Sapporo, Tsukuba, Morioka, Kita-Gun
2017-03-24
Rows per page Showing 1–46 of 46
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Japanese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 22 October 2026. https://priyalifescience.com/clinical-trials-japan/city/tsukuba

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Japan and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,493 studies in total at the last sync on 22 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 46 of those studies with a site in Tsukuba.

How many clinical trials are recruiting in Tsukuba?

16 of the 46 studies on this page are recruiting new participants as of the 22 Oct 2026, 03:19 UTC sync. A further 0 have not yet opened recruitment, 29 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Tsukuba), 46 studies
PhaseStudiesRecruitingShare
Phase 328660.9%
Phase 28617.4%
Observational5310.9%
Not applicable214.3%
Phase 2/3204.3%
Phase 1102.2%

Most active sponsors

Lead sponsors with the most studies (Tsukuba)
Lead sponsorStudiesRecruiting
Merck Sharp & Dohme LLC81
AbbVie40
argenx32
Bristol-Myers Squibb31
Novartis Pharmaceuticals32
Seagen, a wholly owned subsidiary of Pfizer30
Amgen21
Otsuka Pharmaceutical Development & Commercialization, Inc.20
Regeneron Pharmaceuticals21
Abbott Medical Devices10
→

Other trial registries in Japan

This register lists Japan studies from ClinicalTrials.gov. Many studies in Japan are registered only in a national registry. We do not copy those records; search them directly:

  • jRCT (Japan Registry of Clinical Trials) — run by the Ministry of Health, Labour and Welfare; trials under Japan's Clinical Trials Act and other clinical research
  • UMIN-CTR — run by the University of Tokyo Hospital's UMIN Center; many academic and investigator-led studies
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.